---
document_datetime: 2023-09-21 22:13:04
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/truvelog-mix-30-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: truvelog-mix-30-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.339123
conversion_datetime: 2025-12-26 21:06:41.252399
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Truvelog Mix 30

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ² / amended on   | Product Information affected3   | Summary        |
|----------------------|-----------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|----------------|
| N/0004               | Minorchangeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification) | 06/07/2023                          |                                            | PL                              |                |
| II/0003/G            | Thiswas an applicationfor agroupofvariations.                                           | 12/05/2023                          | n/a                                        |                                 | Not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | B.I.a.2.c-Changes in the manufacturing process of the AS-The change refers to a [-] substance in the manufactureofabiological/immunologicalsubstance which may have a significant impact on the medicinal product andisnotrelated toaprotocol B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specificationparameter to the specification with its corresponding test method B.I.a.1.j-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Replacementoradditionofasitewherebatch control/testingtakesplaceand anyofthetest methodatthesiteis abiol/immunolmethod B.I.a.4.a - Change to in-process tests or limits appliedduring themanufactureof theAS- Tightening of in-process limits B.I.a.4.b-Change to in-process tests or limits appliedduring themanufactureof theAS-Addition of a newin-processtest andlimits B.I.b.1.b -Change in the specification parameters and/or limits of anAS,starting material/intermediate/reagent-Tighteningof   |            |            |       |                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------|--------------------------------|
| PSUSA/1749/ 202209 | PeriodicSafetyUpdateEUSingleassessment- insulin aspart                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/04/2023 | n/a        |       | PRACRecommendation-maintenance |
| T/0001             | Transfer ofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/12/2022 | 16/12/2022 | SmPC, |                                |

<div style=\"page-break-after: always\"></div>

| Labelling and   |
|-----------------|
| PL              |